European Commission logo
polski polski
CORDIS - Wyniki badań wspieranych przez UE
CORDIS
Zawartość zarchiwizowana w dniu 2024-05-28

Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe

Cel

Traumatic brain injury (TBI) is among the leading causes of death and disability and the main cause of death among the under-45s. Most patients with moderate to severe TBI are admitted to intensive care units (ICUs)
The “PROSAFE” ICU network was recently established in 6 European countries through EU funding (PHEA 2007331), and has continued to collect high-quality data beyond the grant duration. In 2011, 225 ICUs had joined PROSAFE, recruiting a total of 73,163 patients, 2,694 of whom were admitted for TBI. Hence the network can expect to enrol 7-9,000 moderate to severe TBI patients in 4 years. The PROSAFE consortium has already focused attention on TBI and has just started collecting additional information on this condition in order to develop a prognostic model to identify centres of excellence in TBI management
Aims of proposal are to consolidate the existing network in order to better describe the epidemiology of moderate-severe TBI in 7 countries (Greece has now joined the consortium); build a prognostic model based on short- and long-term outcome measures; identify most effective clinical interventions for optimally treating TBI patients, and recognize the determinants of optimal vs suboptimal performance
All TBI-CDEs endorsed by InTBIR will be collected, along with other items needed to develop a sensible prognostic model, permitting the consortium to join forces with international collaborative initiatives in the field
Availing of the coordinating institute’s biobank and consolidated expertise in biochemical and genetic biomarkers, the aim is to identify prognostic markers and underlying genetic factors influencing response to treatment and final outcome
The PROSAFE consortium is thus in a position to guarantee superior quality data collection in 7 countries and ensure it continues beyond the life of the project. These conditions are essential if the consortium is to contribute to Europe playing a key role in the success of the InTBIR initiative

Zaproszenie do składania wniosków

FP7-HEALTH-2013-INNOVATION-1
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
Wkład UE
€ 2 310 313,76
Adres
VIA MARIO NEGRI 2
20156 Milano
Włochy

Zobacz na mapie

Region
Nord-Ovest Lombardia Milano
Rodzaj działalności
Research Organisations
Kontakt administracyjny
Guido Bertolini (Dr.)
Linki
Koszt całkowity
Brak danych

Uczestnicy (9)